Scotland Fails To Recommend Orkambi But 'New Medicines Fund' Should Enable Access

The Scottish Medicines Consortium (SMC) on May 9 published advice mirroring that of its neighbor NICE failing to recommend the use of Vertex's Orkambi on the UK's NHS for the treatment of cystic fibrosis. This comes despite positive reimbursement decisions in other European countries. However, Scotland's New Medicines Fund should ensure there is a route available for patients to access the medicine, Vertex believes.

Inhalation Through Oxygen Mask
• Source: Shutterstock

In March, NICE, the HTA body for England and Wales, said it recognized the clinical benefits of Vertex Pharmaceuticals Inc.'sOrkambi (lumacaftor/ivacaftor) in the treatment of cystic fibrosis (CF) but treatment costs in relation to its health benefits were not sufficient to recommend its use (Also see "'No Surprise' Says Vertex As NICE Fails To Recommend Orkambi In CF" - Scrip, 23 March, 2016.). The SMC says it agrees with NICE's conclusion on Orkambi and will also not be recommending the use of Kalydeco (ivacaftor) in younger children.

More from Drug Pricing

More from Scrip

BeiGene Ends Anti-TIGIT Development In Lung Cancer

 
• By 

BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.

Vanrafia Approval Plays Into Novartis’s Multipronged IgAN Approach

 

The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.

Orphans Cling On To Growth Advantage As Market Share Heads Towards 20%

 

It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.